DiaMedica Therapeutics Inc. - DMAC STOCK NEWS

DiaMedica Therapeutics (Nasdaq: DMAC) provided a business update and financial results for the year ending December 31, 2021, highlighting a strong balance sheet with $45M in cash, offering a runway into 2024. The company is currently dosing patients in the pivotal Phase 2/3 ReMEDy2 trial for acute ischemic stroke, which aims to enroll 350 patients. New executive appointments were announced, enhancing the leadership team. R&D expenses slightly increased to $8.8M, while general and administrative expenses grew to $4.9M. A conference call is scheduled for March 15, 2022, to discuss these results.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) will release its fourth quarter 2021 financial results after market close on March 14, 2022. A live conference call to discuss these results and provide a business update will take place on March 15, 2022, at 7:00 AM CT. Interested parties can participate via dial-in or webcast. DiaMedica is focused on novel treatments for neurological disorders and kidney diseases, with its lead candidate DM199 targeting acute ischemic stroke and chronic kidney disease.

DiaMedica Therapeutics (NASDAQ: DMAC) announced the appointment of Dominic Cundari as Chief Commercial Officer, focusing on the commercial launch of DM199 for acute ischemic stroke. With over 20 years in specialty biopharmaceuticals, Cundari previously held senior roles at Genentech, enhancing their vascular franchise. The company granted him inducement stock options for 165,000 shares at $2.90 each. DM199, a synthetic form of KLK1, is under FDA's Fast Track Designation for the treatment of acute ischemic stroke, aiming to improve outcomes for untreated patients.

DiaMedica Therapeutics (NASDAQ: DMAC) will present two abstracts at the American Heart Association 2022 International Stroke Conference in New Orleans from February 9-11, 2022. The abstracts focus on:

• Stroke Recurrence and Mortality with Recombinant Tissue Kallikrein Protein in the Remedy1 Phase 2 Trial
• Randomized, Double-blind, Placebo-controlled Study to Evaluate DM199 for Acute Ischemic Stroke (ReMEDy2 Trial)

Presentations will occur on February 10, 2022, from 12:30 PM to 1:15 PM at Poster Hall B2. Visit DiaMedica's website for more details.

DiaMedica Therapeutics has appointed Kirsten Gruis, M.D., as the new Chief Medical Officer. With 20 years of experience in neurology and drug development, Dr. Gruis aims to advance the company’s lead candidate, DM199, towards critical data for acute ischemic stroke. DM199 has shown promise in improving recovery outcomes and reducing recurrent strokes. An inducement grant of 160,000 stock options was also issued to Dr. Gruis, effective January 3, 2022, with an exercise price of $3.88 per share.

DiaMedica Therapeutics Inc. (NASDAQ: DMAC) announced its participation in the LifeSci Partners 11th Annual Corporate Access Event, taking place virtually from January 5-7, 2022. The management team will engage in one-on-one meetings with investors during the event to discuss company developments. DiaMedica focuses on developing novel treatments for neurological disorders and kidney diseases, with lead candidate DM199 showing promising early clinical results. The company is advancing its pivotal ReMEDy Phase 2/3 trial for acute ischemic stroke and completing enrollment in the REDUX Phase 2 trial for chronic kidney disease.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) will have President and CEO Rick Pauls participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference. One-on-one meetings will also be available. The presentation recording will be accessible starting on November 22, 2021, at 10:00 a.m. ET. DiaMedica is focused on developing DM199, a therapeutic for acute ischemic stroke and chronic kidney disease, with ongoing pivotal trials underway. More details can be found on their website.

DiaMedica Therapeutics (Nasdaq: DMAC) announced significant advancements in its programs with the first patient dosed in the Phase 2/3 ReMEDy2 trial for acute ischemic stroke (AIS). The FDA granted Fast Track Designation to DM199 for AIS treatment, enhancing the drug's development timeline. The company's recent $30 million private placement strengthened its balance sheet, raising cash to $48.1 million. R&D expenses increased slightly, totaling $2.3 million for Q3 2021, while G&A costs fell to $1.1 million.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, will participate in the 12th Annual Craig-Hallum Alpha Select Conference on November 16, 2021. Management is available for one-on-one meetings, and interested investors can contact their Craig-Hallum representative to schedule. DiaMedica’s lead candidate, DM199, is aimed at treating acute ischemic stroke and chronic kidney disease. The company has initiated the ReMEDy Phase 2/3 trial for acute ischemic stroke and is completing enrollment in the REDUX Phase 2 trial for chronic kidney disease.